Stocktoria
enGene Therapeutics Inc. ENGN
Nasdaq · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2021-12-10
enGene Therapeutics Inc. statistics & valuation
Market cap as of 2026-07-01. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Return on assets | -53.0% | -17.7% | -114.9% | -102.3% |
| Return on equity | -69.9% | -20.2% | -137.8% | 31.9% |
| Current ratio | 6.30 | 16.87 | 16.25 | 4.42 |
Source: SEC EDGAR filings · CIK 0001980845 · US · as of 2025-10-31. facts plus Stocktoria's own computed scores — not investment advice.